NIH Press Release
National Institute of Allergy and
Infectious Diseases

Monday, September 29, 1997

Cheryl Parrott
(301) 402-1663

First Grants For Innovative AIDS Vaccine Research Awarded

The National Institute of Allergy and Infectious Diseases (NIAID) has selected the first grant recipients in its new program to foster innovative research on AIDS vaccines. Earlier this year, NIAID announced the INNOVATION Grant Program for Approaches in HIV Vaccine Research, designed to speed the pace of discovery and development in vaccines to prevent HIV disease.

"President Clinton has challenged the nation to develop a vaccine against AIDS in the next 10 years," said Health and Human Services Secretary Donna E. Shalala. "These grants will help to foster the kind of fresh, innovative thinking we need to achieve that goal."

"We are extremely pleased by the overwhelming response to this announcement. The 49 grants we are funding will explore creative approaches to vaccine design and involve many investigators new to AIDS research," commented NIAID Director Anthony S. Fauci, M.D.

NIAID awarded the 49 grants, totaling more than $11.8 million, after an exhaustive evaluation of more than 100 applications. The grants will be for either one- or two-year funding periods. The grant recipients, 28 of whom are new to NIAID's extramural research program, will be conducting research within the following areas: understanding the structure and function of the HIV envelope protein; improving animal models for vaccines and studies on the causes and progression of disease; and understanding the mechanisms of antigen processing in living organisms to maximize the immune response.

NIAID created the INNOVATION Program to encourage novel ideas and approaches while stimulating interest from a new group of scientists, including those who had not been involved in HIV research. The AIDS Vaccine Research Committee (AVRC) chaired by David Baltimore, Ph.D., president-designate of the California Institute of Technology, endorsed the concept of the INNOVATION Program.

"Traditional killed vaccine or live attenuated vaccine development methods are being pursued, but may not be the most successful for HIV," said Dr. Baltimore. "To discover the best way to tame HIV infection, we need also to focus on the newer biomedical technologies and approaches that depart from the conventional."

The grant recipients will be conducting research to:

The grantees are:

Because of the importance and urgency that NIAID and the AVRC place on AIDS vaccine development, NIAID piloted a new streamlined grant award process with this program announcement. NIAID published the call for applications in March 1997 and selected recipients within six months. Based on the encouraging response from the scientific community, a second program announcement is planned.

NIAID, a component of the National Institutes of Health (NIH), conducts and supports research to prevent, diagnose and treat illnesses such as AIDS and other sexually transmitted diseases, tuberculosis and malaria, as well as asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

Press releases, fact sheets and other NIAID-related materials are available on the Internet via the NIAID home page at